Commentary: Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling
Saved in:
| Main Authors: | Giulia Valdiserra, Clelia Di Salvo, Matteo Fornai, Luca Antonioli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1604337/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Off-label dermatologic uses of IL-23 inhibitors
by: Justin Porter, et al.
Published: (2024-12-01) -
Successful treatment of pyoderma gangrenosum with guselkumab
by: Sofia Botvid, et al.
Published: (2025-03-01) -
Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01) -
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease
by: D'Amico F, et al.
Published: (2025-05-01) -
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-07-01)